神経ホルモンの活性化とコンバーティング酵素阻害剤への反応は,閉塞性心不全で起こります
1Cardiovascular Division University of Minnesota, Minneapolis 55455.
Circulation
|February 1, 1990
まとめ
神経ホルモンの血管収縮システムは,心不全で活性化しますが,その活性化は均一ではありません. 変換酵素阻害剤は血液動力学を改善しますが,これらのシステムに対する長期的な影響は不明です.
科学分野:
- 心血管医学 心血管医学
- ネフロロジーはネフロロジーを用います.
- 薬理学 薬理学とは
背景:
- 神経ホルモンの静脈縮器系は,充血性心不全 (CHF) でしばしば活性化されます.
- これらのシステムは,CHF患者において見られる異常な血管収縮に寄与する.
研究 の 目的:
- 血レニン活性とノレピネフリン濃度の分布をCHF患者で調査する.
- これらのマーカーと血液動力学,人口統計学,腎臓の因子の相関性を調べる.
- CHFの血液動力学と神経ホルモン系に変換酵素阻害剤の影響を評価する.
主な方法:
- 血レニン活性とノレピネフリンレベルを177人のCHF患者で分析した.
- 血液動力学的測定値,年齢,腎機能との相関分析.
- 変換酵素阻害剤の動脈トーン,プレロード,および心電量に対する影響の評価.
主要な成果:
- 血レニン活性とノレピネフリン濃度の広範な分布は,非均一な活性化を示す.
- これらのマーカーと血液動力学的パラメータ,年齢,腎機能の間の相関は弱い.
- 変換酵素阻害剤は有益な血液動力学的効果を示し,動脈のトーンとプレロードを低下させ,心電量を増大させました.
結論:
- CHFにおけるレニン=アニオテンシン系と交感性神経系の活性化は,複雑で多因性である.
- 変換酵素阻害剤は,CHFにおける血液動力学的利点を提供します.
- これらの阻害剤が神経ホルモンマーカーに与える長期的影響とその相互作用については,さらなる調査が必要である.
関連する概念動画
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...